Module

Hepatitis Journal Club: Top Clinical Articles of 2007-08

Source: Hepatitis Annual Update 2008

Hepatitis Journal Club: Top Clinical Articles of 2007-08

Co-Chair: Raymond T. Chung, MD

Faculty:

Jorge L. Herrera, MD

CREDIT INFORMATION

Release Date: July 03, 2008

Expiration Date: July 02, 2009

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.0 Nursing contact hour

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount the top 5-10 clinical findings in liver disease between February 2007 and February 2008
Discuss how the top findings in liver disease over the past year have advanced the field
Describe what changes in clinical practice will come about from the top advances in liver disease over the past year

Topics covered include:

Introduction
Individualizing Therapy for Patients With Genotype 2 or 3 HCV Infection
Duration of Therapy in Patients with Genotype 1 Infection
Importance of Ribavirin Dose in Treating Chronic Hepatitis C Infection
Management of Comorbidities in Patients With Hepatitis C Infection
Approach to Hepatitis C Patients With Advanced Fibrosis
Treatment of Hepatitis B and HIV Coinfection
Safety of Peginterferon in Hepatitis B Cirrhosis
New Options for Patients With Decompensated Liver Disease
Hepatitis E Virus in Organ Transplantation Recipients
Extracorporeal Albumin Dialysis for Advanced Cirrhosis With Encephalopathy
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.